Zobrazeno 1 - 10
of 3 654
pro vyhledávání: '"S, Ishioka"'
Autor:
Touchette, Hugo
This brief note argues that, contrary to the claim of Ishioka and Fuchikami (chao-dyn/9902012), Landauer's principle is concerned a priori with entropy generation in computing processes. The concept of heat, in this principle, is only relevant when a
Externí odkaz:
http://arxiv.org/abs/chao-dyn/9902017
Autor:
Tetsuya Sakashita, Shojiro Matsumoto, Shigeki Watanabe, Hirofumi Hanaoka, Yasuhiro Ohshima, Yoko Ikoma, Naoyuki Ukon, Ichiro Sasaki, Tatsuya Higashi, Tetsuya Higuchi, Yoshito Tsushima, Noriko S. Ishioka
Publikováno v:
EJNMMI Physics, Vol 8, Iss 1, Pp 1-15 (2021)
Abstract Background We recently reported a new absorbed dose conversion method, RAP (RAtio of Pharmacokinetics), for 211At-meta-astatobenzylguanidine (211At-MABG) using a single biodistribution measurement, the percent injected dose/g. However, there
Externí odkaz:
https://doaj.org/article/8fb5e853cf504cbdb67b00c25c6997b4
Publikováno v:
Mechanical Engineering Journal, Vol 9, Iss 4, Pp 21-00397-21-00397 (2022)
For the mass production of astatine-211, a promising radiopharmaceutical for cancer treatment, we have proposed the innovative “Liquid Bismuth Target System.” The target window in this system must be made from a material that resists the highly c
Externí odkaz:
https://doaj.org/article/1623a302f1ac4177a2e64ac1c939ab06
Autor:
Aiko Yamaguchi, Arifudin Achmad, Hirofumi Hanaoka, Yusri Dwi Heryanto, Anu Bhattarai, Ratianto, Erdene Khongorzul, Rini Shintawati, A. Adhipatria P. Kartamihardja, Ayaka Kanai, Yumi Sugo, Noriko S. Ishioka, Tetsuya Higuchi, Yoshito Tsushima
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Backgrounds Overexpression of epidermal growth factor receptor (EGFR) has been established as a valid therapeutic target of non-small cell lung cancer (NSCLC). However, the clinical benefit of cetuximab as an EGFR-targeting drug is still con
Externí odkaz:
https://doaj.org/article/6463ecc333884153b0f98a1deb61083e
Autor:
Hitomi Sudo, Atsushi B. Tsuji, Aya Sugyo, Kotaro Nagatsu, Katsuyuki Minegishi, Noriko S. Ishioka, Hiroshi Ito, Keiichiro Yoshinaga, Tatsuya Higashi
Publikováno v:
Translational Oncology, Vol 12, Iss 7, Pp 879-888 (2019)
The α-emitter 211At-labeled meta-astatobenzylguanidine (211At-MABG) has a strong antitumor effect on pheochromocytoma xenograft tumors and holds great promise as a new therapeutic option for malignant pheochromocytoma. To evaluate the acute radiatio
Externí odkaz:
https://doaj.org/article/a4107be736524f219d817f4291e137e4
Autor:
Syohei Obata, Yumi Sugo, Hinako Manabe, Yuto Arima, Kei Toda, Noriko S. Ishioka, Masanobu Mori, Shin-Ichi Ohira
Publikováno v:
Analytical Sciences. 39:671-677
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c1278f7f6f13d5dafdda7e0bb4cb776
https://doi.org/10.1007/s44211-022-00254-9
https://doi.org/10.1007/s44211-022-00254-9
Publikováno v:
Molecules, Vol 26, Iss 16, p 4977 (2021)
(1) Background: Deferoxamine B (DFO) is the most widely used chelator for labeling of zirconium-89 (89Zr) to monoclonal antibody (mAb). Despite the remarkable developments of the clinical 89Zr-immuno-PET, chemical species and stability constants of t
Externí odkaz:
https://doaj.org/article/2234b7420f6e442eb03ac656943dc40f
Autor:
Yasuhiro Ohshima, Ichiro Sasaki, Shigeki Watanabe, Tetsuya Sakashita, Tatsuya Higashi, Noriko S. Ishioka
Publikováno v:
Nuclear Medicine and Biology. :44-51
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff2b79395ec0cbab335d40d9c9350380
https://doi.org/10.1016/j.nucmedbio.2022.06.005
https://doi.org/10.1016/j.nucmedbio.2022.06.005
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.